Shanghai state-owned shares have these.After-hours big profits are related to mergers and acquisitions, restructuring, Shanghai state-owned shares have these.Analysts said that the plan is expected to benefit Shanghai local stocks from multiple dimensions.
Shanghai state-owned shares have these.Among them, the market value of chip leader SMIC A shares exceeded 170 billion yuan, ranking first. According to the data, SMIC is one of the world's leading integrated circuit wafer foundry enterprises, and it is a professional wafer foundry enterprise with advanced technology, the largest scale, the most complete supporting services and transnational operation.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.
In the secondary market, the concept stocks of M&A and restructuring rose strongly, and the restructuring index rose nearly 63% since September 24th.Among them, the market value of chip leader SMIC A shares exceeded 170 billion yuan, ranking first. According to the data, SMIC is one of the world's leading integrated circuit wafer foundry enterprises, and it is a professional wafer foundry enterprise with advanced technology, the largest scale, the most complete supporting services and transnational operation.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.
Strategy guide
12-13
Strategy guide 12-13
Strategy guide
12-13